Metagenomi Therapeutics Inc (MGX) Stock Analysis
Verdict: AVOID
Critical cash runway exhaustion (<6 months) and widening earnings misses force an impending dilutive capital raise near historic lows.
Investment score: 23/100
Analysis as of
Is Metagenomi Therapeutics Inc stock worth reviewing? The TradeMates thesis
The TradeMates model issues an AVOID rating on Metagenomi Therapeutics (MGX) due to severe cash burn, immediate dilution risk, negative operating margins (-415%), and persistent earnings misses.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 25/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
Metagenomi Therapeutics Inc opportunities and risks
What speaks for MGX
- Genome editing toolkit partnerships with ModernaTX and Ionis Pharmaceuticals
What speaks against MGX
- Imminent capital raise and severe equity dilution
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| MGX | n/a | 3.2x | n/a | 74.3% | -689.2% | -198.2% |
| ELTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -111.7% |
| HOWL | n/a | 2.1x | n/a | 86.4% | -164.8% | -67.5% |
| ANVS | n/a | 0.0x | n/a | 0.0% | 0.0% | -98.0% |
| MCRB | n/a | 21.7x | n/a | 82.6% | -1192.9% | -125.8% |
| HRGN | n/a | 47.1x | n/a | -5.7% | -778.0% | -9.0% |
| Peer median | n/a | 2.1x | n/a | 0.0% | -164.8% | -98.0% |
Frequently asked questions about Metagenomi Therapeutics Inc (MGX)
Is MGX stock a good investment?
The TradeMates model rates Metagenomi Therapeutics Inc as AVOID with an investment score of 23/100. The TradeMates model issues an AVOID rating on Metagenomi Therapeutics (MGX) due to severe cash burn, immediate dilution risk, negative operating margins (-415%), and persistent earnings misses. This is algorithmic model output, not personal investment advice.
Is MGX stock a buy?
The TradeMates model verdict for MGX is AVOID with an investment score of 23/100. Treat this as a model signal to review, not a personal buy recommendation.